Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Director Anthony G. Quinn acquired 7,956 shares of the stock in a transaction on Monday, December 4th. The stock was bought at an average cost of $4.98 per share, for a total transaction of $39,620.88. Following the transaction, the director now owns 14,100 shares of the company’s stock, valued at approximately $70,218. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Aeglea Bio Therapeutics Inc (NASDAQ AGLE) traded down $0.34 during mid-day trading on Tuesday, reaching $4.74. 76,239 shares of the company’s stock traded hands, compared to its average volume of 65,901. Aeglea Bio Therapeutics Inc has a twelve month low of $2.81 and a twelve month high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.07. The business had revenue of $1.26 million for the quarter. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. equities analysts forecast that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of AGLE. Bank of New York Mellon Corp bought a new stake in shares of Aeglea Bio Therapeutics in the first quarter valued at approximately $157,000. Renaissance Technologies LLC bought a new stake in shares of Aeglea Bio Therapeutics in the first quarter valued at approximately $270,000. Vanguard Group Inc. raised its position in shares of Aeglea Bio Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 12,966 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of Aeglea Bio Therapeutics in the second quarter valued at approximately $653,000. 46.89% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research report on Friday, November 10th.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with's FREE daily email newsletter.